Delayed emesis induced by moderately emetogenic chemotherapy: Do we beed to treat all patients?

Annals of Oncology

Volumn 8, Issue 6, 1997, Pages 561-567

  Roila, Fausto ^a  

^a Policlinico Hospital   (Italy)

Author keywords

Delayed emesis; Moderately emetogenic chemotherapy

Indexed keywords

EID: 0006651162     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Roila F. To mit o M. Ballatori E et al. Comparative studies of various antiernetic regimens. Support Care Cancer 1996; 4: 270 80.
2. Kaizer L. Warr D, Hoskins P et ai. Effect of schedule and maintenance on the anticmctic efficacy of ondansetror. combined with de.xameihasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. ,i Clin Oncol 1994: 12: 1050-7.
3. K.OO WH. A n g PT. Roie of maintenance oral dexamelhasone in prophylaxis oi" delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996: 7: 71-4.
4. Tonato M. Roila r. Del Favcro A. Methodology of anticmctic triais: A review. Ann Oncol 199i; 2: 107-14.
5. The Italian Group for Antiemetic Research. Dexame'.hasone. granisetron, or both for :he pre\enlion of nausea and vomiting during chemotherapy for cancer. K Engi J Med i995: 332: 1-5.
6. The Italian Group for Antiemetic Research. Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 1995: 13: 24i-26.